AxoGen, Inc. (AXGN)
(Delayed Data from NSDQ)
$21.61 USD
-0.89 (-0.89%)
Updated Mar 3, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank | Definition | Annualized Return |
---|---|---|
1 | Strong Buy | 24.41% |
2 | Buy | 17.88% |
3 | Hold | 9.48% |
4 | Sell | 5.03% |
5 | Strong Sell | 1.87% |
S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value Score | A |
---|---|
Growth Score | A |
Momentum Score | A |
VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value B Growth F Momentum D VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Zacks News
AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AXGNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AXGNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXGNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXGNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
AXGNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXGNNegative Net Change
consensus-outlook earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
AxoGen (AXGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
AXGNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXGNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AXGNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise energy industry-outlook zacks-consensus-estimate zacks-rank
Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXGNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
MASINegative Net Change DXCMNegative Net Change WMGIPositive Net Change AXGNNegative Net Change
medical
What's in Store for Humana (HUM) Stock in Q4 Earnings?
by Zacks Equity Research
Higher enrollment and strong segmental results are expected to help Humana (HUM) in fourth-quarter earnings.
AXGNNegative Net Change MOHNegative Net Change HUMNegative Net Change THCPositive Net Change
medical
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
AXGNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
AxoGen (AXGN) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXGNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
SYKNegative Net Change PENNegative Net Change MZORNo Net Change MDTPositive Net Change JNJNegative Net Change IARTNegative Net Change EWNegative Net Change BAXNegative Net Change AXGNNegative Net Change ABTNegative Net Change
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
DWASNegative Net Change PLUSPositive Net Change MRTXNegative Net Change AXGNNegative Net Change
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1
by Zacks Equity Research
Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.
AGNPositive Net Change RDYPositive Net Change TEVAPositive Net Change AXGNNegative Net Change
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for DWAS
DWASNegative Net Change MGPINegative Net Change MRTXNegative Net Change AXGNNegative Net Change
Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for DWAS
DWASNegative Net Change NEOGNegative Net Change MRTXNegative Net Change AXGNNegative Net Change
Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
DWASNegative Net Change MGPINegative Net Change NEOGNegative Net Change AXGNNegative Net Change
Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
DWASNegative Net Change AXGNNegative Net Change ASGNPositive Net Change MDGLNegative Net Change
AxoGen (AXGN) Enters Overbought Territory
by Zacks Equity Research
AxoGen, Inc. (AXGN) has moved higher as of late, but there could definitely be trouble on the horizon for this company
AXGNNegative Net Change
Mylan (MYL) Surges: Stock Moves 16.2% Higher
by Zacks Equity Research
Mylan N.V. (MYL) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes.
MYLPositive Net Change AXGNNegative Net Change
AxoGen (AXGN) Shows Strength: Stock Adds 6.1% in Session
by Zacks Equity Research
AxoGen, Inc. (AXGN) shares rose a little above 6% in the last trading session.
AXGNNegative Net Change CORIPositive Net Change
Zacks.com featured highlights: AxoGen, MAG Silver, Triumph Bancorp, UCP and Yelp
by Zacks Equity Research
Zacks.com featured highlights: AxoGen, MAG Silver, Triumph Bancorp, UCP and Yelp
AXGNNegative Net Change MAGNegative Net Change TBKPositive Net Change